"The prostate compound developed at Thomas Jefferson University may provide a noninvasive early and more accurate imaging technique to (a) localize primary PC, that will guide biopsy; (b) detect recurrent disease; (c) image metastatic disease; and (d) determine effectiveness of treatment,” said Dr. Mathew Thakur, professor of radiology and director and lead investigator. Developments in genomics and proteomics have shed light on the genesis of many diseases, including PC. PC cells express oncogene product VPAC1 exogenously in a large number. These specific fingerprints express themselves at a very early stage, well before cell morphology has altered for histologic confirmation, and even well before the elevation of PSA [prostate-specific antigen]. We hypothesize that targeting elevated VPAC1 with gene-guided radioactive probe for molecular imaging of PC will permit us to contribute toward this need. During the past 10 years, the Thakur laboratory at Thomas Jefferson University has gained extensive experience in successfully targeting these biomarkers with Tc-99m or Cu-64 labeled specific peptides, for early and accurate diagnosis of pancreatic and breast cancers in animals as well as in humans by planar, SPECT [single photon emission tomography] and PET [positron emission tomography] imaging. The early data for PET imaging of PC by Cu-64-peptide are highly encouraging,” said Dr. Thakur.

Among men in the United States, PC is the most deadly disease, second only to the cancers of the lung and bronchus combined. Statistical data indicate that PC affects one male in every six who are older than 60 years of age and the risk continues to rise as life expectancy increases. Although great advances have been made in the diagnosis and treatment of PC, 29,500 men succumbed to PC in 2007 alone. Early diagnosis of PC can necessitate aggressive therapeutic intervention; greatly improve the management of disease, and save patients from morbidity and mortality. Two prominent diagnostic tests for PC, namely the determination of PSA and the transrectal ultrasound (TRUS), suffer from serious limitations and require invasive systemic biopsy for histologic confirmation, considered to be the gold standard. In 2007, an estimated 750,000 prostate biopsies were performed, more than two-thirds of which had benign pathology, leading to a major ineffectiveness. Inaccurate or unreliable diagnosis results in under-, or over-treatment of patients leading to minimal benefits, incontinence, and/or impotence and significant loss of health care resources.

NuView CEO Paul Crowe, said, "The benefits from this MI biomarker are clear. If potentially terminal conditions such as prostate cancer can be accurately detected before manifesting into a structural change, patient outcomes would greatly improve, and healthcare costs would decline. MI is noninvasive, so the need for exploratory surgery would also be reduced, and MI can be used to track the progress and response from drug therapies or other treatments, enabling the physician to monitor and quickly respond to their patient's condition.”

NuView medical director Peter Conti, M.D. added, "This development of genomics-based molecular imaging diagnostics is very promising and may, with alterations to the biomarkers original complex, become a companion or paired targeted therapeutic. The potential for pairing a molecular diagnostic and a targeted therapy based on the individual patient characteristics, will contribute to the growing trend towards more efficient personalized medicine. We are pleased to part of this new frontier in medicine that should provide physicians with new approaches for diagnosis and treatment of medical disorders.” Dr. Conti is a professor of biomedical engineering, radiology, and pharmacy at the University Of Southern California (Los Angeles, USA).

Related Links:
Thomas Jefferson University
NuView Life Sciences